Bristol-Myers Squibb, Celgene plan to combine in $74 billion deal
( January 3, 2019, 16:21 GMT | Official Statement) -- MLex Summary: Bristol-Myers Squibb announced plans to buy Celgene in a $74 billion transaction the company said will create a top focused specialty biopharma company with complementary areas of focus. The deal is expected to close in the third quarter of 2019.Statement follows in full....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.